Retatrutide's triple GLP-1/GIP/glucagon mechanism produces the highest HbA1c reduction of any GLP compound in Phase 2 trials — plus an 82% reduction in liver fat, addressing the insulin resistance driven by NAFLD in type 2 diabetes.
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 agonism stimulates glucose-dependent insulin secretion and suppresses glucagon. GIP agonism provides additive insulin secretion and improves adipose insulin sensitivity. Glucagon receptor agonism — unique to retatrutide among approved and late-stage GLP compounds — drives hepatic fat mobilization, increasing energy expenditure and clearing the liver fat that is a primary driver of insulin resistance in type 2 diabetes. Phase 2 data showed an 82% relative reduction in liver fat content, the largest observed for any GLP compound in clinical trials.
| Compound | Mechanism | HbA1c | Weight | Status |
|---|---|---|---|---|
| Retatrutide | Triple GLP-1/GIP/Glucagon | −2.2% | −17.5 kg | Phase 3 (2026) |
| Tirzepatide (Mounjaro) | Dual GLP-1/GIP | −2.0% | −8.5 kg | Yes (2022) |
| Semaglutide (Ozempic) | GLP-1 agonist | −1.5% | −4.5 kg | Yes (2017) |
| Liraglutide (Victoza) | GLP-1 agonist | −1.2% | −3.0 kg | Yes (2010) |
Yes. Retatrutide is in Phase 3 clinical trials (TRIUMPH program) that include type 2 diabetes as a primary indication alongside obesity. Phase 2 data showed HbA1c reductions of approximately 2.2% — exceeding tirzepatide and semaglutide. FDA approval for diabetes is anticipated in 2026-2027.
Glucagon receptor agonism in retatrutide drives hepatic fat mobilization and increases energy expenditure beyond what GLP-1/GIP agonism alone achieves. In diabetic patients with non-alcoholic fatty liver disease (NAFLD) — which is highly prevalent in type 2 diabetes — retatrutide's glucagon activity produced an 82% relative reduction in liver fat in Phase 2 trials, addressing a key driver of insulin resistance.
Phase 2 data shows retatrutide produces greater HbA1c reduction (−2.2% vs −2.0%) and substantially greater weight loss (−17.5 kg vs −8.5 kg) compared to tirzepatide. The addition of glucagon receptor agonism provides hepatic fat clearance and energy expenditure benefits that tirzepatide's dual GLP-1/GIP mechanism does not. Phase 3 head-to-head data is pending.
Phase 2 diabetes trials used doses of 1 mg, 4 mg, 8 mg, and 12 mg weekly, with 12 mg producing the greatest HbA1c and weight loss outcomes. Phase 3 TRIUMPH trials are evaluating similar dose ranges. Research protocols are based on Phase 2 data pending Phase 3 completion.
Yes. Retatrutide's glucagon receptor agonism drives hepatic fat mobilization. Phase 2 data showed an 82% relative reduction in liver fat content — the largest reduction observed for any GLP compound in clinical trials. This is particularly relevant for type 2 diabetes patients, where NAFLD prevalence exceeds 70%.
Retatrutide is currently in Phase 3 TRIUMPH trials with a diabetes indication. FDA approval is anticipated in 2026-2027 pending trial completion and regulatory review. It is currently available as a research peptide.
Purgo Labs provides pharmaceutical-grade retatrutide with third-party COAs. Use code HEALTH for 15% off.
Buy Retatrutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.